(DTIL) Precision BioSciences, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DTIL) Precision BioSciences, Inc. Complete Analysis Pack
See the Bigger Picture
This Precision BioSciences, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. The page already shows a real preview of the analysis, so you can review the actual content and format before buying. Purchase the full version to get the complete ready-to-use report.
Stars
ARCUS platform
ARCUS is Precision BioSciences, Inc.'s core genome-editing engine, powering both in vivo and ex vivo programs and keeping the platform in the Star quadrant as the company scales. In 2025, its lead programs included PBGENE-HBV and PBGENE-DMD, while the gene-editing market was still growing at a double-digit pace. That mix of platform control and market growth makes ARCUS the company’s most strategic asset.
PBGENE-HBV
PBGENE-HBV is Precision BioSciences, Inc.'s lead in vivo gene-editing program for chronic hepatitis B, a disease that affects about 254 million people worldwide. Current antiviral care rarely clears infection, so the unmet need is large. If early clinical signals hold, this could be one of Precision BioSciences, Inc.'s highest-upside Stars in the BCG Matrix.
Servier alliance
Precision BioSciences’ Servier alliance expands allogeneic CAR T work across multiple targets, strengthening the company’s cell-therapy pipeline. The partnership gives external validation in a market that is expected to exceed $10 billion by 2030, while also shifting some development burden to a larger pharma partner. It is one of Precision’s strongest commercial ties and a clear Stars asset.
iECURE collaboration
The iECURE deal pushes Precision BioSciences, Inc.’s ARCUS platform into gene-editing therapeutics beyond its wholly owned pipeline, so it widens reach without full balance-sheet risk. That fits a Star-style position: high growth, high strategic value, and a partner-backed path to broader clinical upside.
- Expands ARCUS into a new therapeutic lane
- Shares cost and development risk
- Raises platform validation with a partner
- Supports high-growth BCG positioning
For Precision BioSciences, Inc., this is less about one asset and more about platform proof. The iECURE collaboration shows ARCUS can move into partnered gene-editing programs, which strengthens long-term optionality.
In vivo editing focus
Precision BioSciences’ in vivo editing push fits a fast-growing gene-editing market, with sector growth often modeled in the low double digits through 2030. By end-2025, the company had concentrated capital and talent on in vivo programs, giving it the profile of a rising core franchise.
- Focused capital on in vivo programs
- Aligned with faster-growing biotech demand
- Rising core franchise profile by end-2025
Precision BioSciences’ ARCUS Star: High-Growth, Partner-Backed
Precision BioSciences, Inc.’s Stars are ARCUS-led programs with clear growth optionality: PBGENE-HBV targets a 254 million-person chronic hepatitis B market, while the Servier alliance and iECURE deal extend ARCUS into partner-backed pipelines. By end-2025, the company had concentrated capital on in vivo editing, fitting a high-growth, high-value BCG Star profile.
| Star asset | Why it fits | Key data |
|---|---|---|
| ARCUS platform | Core engine | In vivo + ex vivo use |
| PBGENE-HBV | High unmet need | 254M chronic HBV cases |
| Servier alliance | Partner validation | Allogeneic CAR T expansion |
What is included in the product
Detailed Word Document
Precision BioSciences BCG Matrix maps its pipeline by growth and market share to spot Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Clean BCG Matrix for Precision BioSciences, Inc. to quickly spot growth, cash, and weak spots.
Reference Sources
Provides a traceable source trail for Precision BioSciences, Inc. that boosts credibility and helps decision-makers validate key assumptions fast.
Cash Cows
0 approved products
Precision BioSciences ended FY2025 with 0 approved commercial products, so it has no true Cash Cow in the BCG sense. The company stayed pre-revenue from marketed therapies, and cash generation still depended on external funding and collaboration inflows. Until an approved product launches, this segment remains a cost center, not a steady cash source.
0 marketed therapies
Precision BioSciences had 0 marketed therapies, so there was no mature product franchise to generate steady cash flow. In the latest reported period, the company remained precommercial, with spending concentrated in research and development rather than product sales. That leaves Cash Cows empty and forces the BCG view toward a cash-burning growth stage.
0 recurring royalties
Precision BioSciences had no meaningful recurring royalty stream by end-2025, so this was not a classic BCG cash cow. Any cash tied to partnerships likely came from upfront payments, milestones, or cost-sharing, not steady royalty income. That matters because recurring royalties usually fund low-growth businesses with predictable cash flow, and Precision BioSciences lacked that base.
Collaboration fees
Precision BioSciences, Inc. gets collaboration fees from Servier, iECURE, and other partners, which can bring upfront cash and milestone payments. That helps fund R&D and operations without commercial product sales, but these inflows are still partnership-linked and not a durable BCG cash cow. In 2025, this kind of revenue remains episodic, not recurring.
- Upfront fees support cash burn.
- Milestones can spike, then fade.
- Not stable enough for cash cow status.
Non-dilutive funding
Precision BioSciences, Inc. has relied on partnership economics, not mature operating cash flow, to fund this cash cow bucket. Research collaboration receipts and other non-dilutive support help extend runway, but they do not show the steady, self-funding cash generation of a true Cash Cow.
So this is a liquidity buffer, not a stable franchise. The mix lowers dilution risk, yet cash still depends on deal flow and milestone timing rather than repeatable operating surplus.
- Research deals fund R&D and runway.
- Not a durable operating cash source.
Precision BioSciences Lacks a Cash Cow in FY2025
Precision BioSciences, Inc. had no Cash Cow in FY2025: 0 approved products, 0 marketed therapies, and no steady royalty stream. Cash came from collaboration fees, milestones, and cost-sharing, so inflows stayed episodic rather than recurring. This is a runway buffer, not a mature cash-generating franchise.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Marketed therapies | 0 |
| Cash cow status | None |
Preview the Actual Deliverable
Precision BioSciences, Inc. Reference Sources
The preview you see for the Precision BioSciences, Inc. BCG Matrix is the exact same document you’ll receive after purchase. There are no hidden changes, demo pages, or watermarks—just the full, ready-to-use file. Download it instantly and use it for strategic analysis, presentations, or planning with confidence.
Dogs
PBCAR0191
PBCAR0191 is an allogeneic anti-CD19 CAR T candidate in Phase 1/2a, so it remains an early-stage asset with no approved product sales. The CD19 market is already crowded, led by commercial products like Novartis' Kymriah and Gilead/Kite's Yescarta, which makes share capture hard. With no commercial share by end-2025, PBCAR0191 fits the Dogs bucket: low share, low near-term cash generation.
PBCAR269A
PBCAR269A is an investigational BCMA-targeting allogeneic CAR T for multiple myeloma, so it sits in a crowded field led by approved drugs like Bristol Myers Squibb's Abecma and Johnson & Johnson's Carvykti. Those two BCMA therapies already have major commercial traction, with 2024 sales of about $327 million and $963 million, which raises the bar for differentiation and market share. For Precision BioSciences, Inc., this makes PBCAR269A a Dogs asset in the BCG Matrix until clear clinical or commercial proof emerges.
PBCAR19B
PBCAR19B fits the Dogs box in Precision BioSciences, Inc.'s BCG Matrix: it is a single-step gene-edit stealth-cell anti-CD19 CAR T concept, but it stayed development-stage through end-2025, with no commercial sales to build share. Early differentiation is real, yet without late-stage data, approvals, or revenue, it does not move the profit pool. Precision BioSciences also remained R&D-led, so this asset looked like a cash user, not a market winner.
CD19 crowding
CD19 crowding is a clear Dog for Precision BioSciences, Inc.: the CD19 CAR-T field is already packed with approved leaders like Kite Pharma’s Yescarta and Novartis’s Kymriah, plus many pipeline rivals. Precision BioSciences, Inc.’s allogeneic model faces heavier competition, so near-term share leadership looks unlikely.
- CD19 CAR-T is already crowded
- Big incumbents have approved products
- Allogeneic approach is harder to win
- Near-term market share upside is weak
Legacy ex vivo CAR T
Precision BioSciences, Inc. legacy ex vivo CAR T assets have not reached commercialization, so in BCG terms they fit the Dog bucket: low market share, weak near-term payoff, and ongoing cash use in a crowded oncology field.
With no late-stage product sales from this older program line, these assets look more like capital drains than growth engines, especially versus 2025/2026 priorities in gene editing and next-gen cell therapy.
- Precommercial
- Crowded oncology market
- Capital use without strong returns
- Most dog-like portfolio segment
Precision BioSciences' Dog Assets Face Crowded CAR-T Rivals
Precision BioSciences, Inc.'s Dog assets stay precommercial through 2025, with no approved sales and weak share in crowded CD19 and BCMA spaces. PBCAR0191 and PBCAR269A face entrenched rivals like Yescarta, Kymriah, Abecma, and Carvykti, so near-term upside is limited. These programs look like cash users, not BCG winners.
| Asset | 2025 status | BCG |
|---|---|---|
| PBCAR0191 | Phase 1/2a | Dog |
| PBCAR269A | Precommercial | Dog |
Question Marks
PBGENE-DMD
PBGENE-DMD fits the Question Marks box in Precision BioSciences, Inc.’s BCG mix: Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 live male births, so the addressable need is large, but PBGENE-DMD is still pre-commercial and had no market share by end-2025. As an ARCUS-based gene-editing program, it has high upside if clinical data land well, but it also carries high execution risk.
HBV curative editing
Chronic hepatitis B affects about 254 million people worldwide and causes roughly 1.1 million deaths a year, so the market need is huge. PBGENE-HBV is still early and has not yet shown clear clinical or commercial traction, while Precision BioSciences, Inc. reported no product revenue in 2025. That makes HBV curative editing a classic question mark: big upside, but unproven.
Solid tumor CAR T
Precision BioSciences, Inc. and Servier have discussed expanding CAR T beyond CD19, and that keeps solid tumors in the question-mark bucket. Solid tumors make up about 90% of cancers, so the prize is huge, but allogeneic CAR T still has not shown clear dominance there. As of 2026, Precision BioSciences, Inc. still has minimal share in this frontier, so the upside is real but unproven.
ARCUS expansion
ARCUS can be extended into multiple new therapeutic uses, so Precision BioSciences, Inc. has real upside if the platform keeps proving itself. But these programs stay "question marks" until more clinical readouts and partner wins show clear demand in a gene-editing market that is still expanding in 2025/2026.
That means the value is mostly in optionality today, not cash flow. One clean signal from a larger Phase 2/3 data set or a new license deal could move ARCUS from a BCG question mark toward a stronger growth asset.
- Broad platform, but limited proof
- More indications can lift value
- Clinical data is the key gate
- Partner adoption will shape scale
New partnered programs
New partnered programs like iECURE and Servier could become Precision BioSciences, Inc. growth shots if expansion data keeps improving. External partners cut cash burn and can speed development, which matters in a biotech market that reached about $1.55 trillion in 2024. Still, these programs stay in the Question Mark bucket until they show stronger clinical and regulatory proof.
- Partnered programs lower funding pressure.
- New targets can add upside fast.
- Data readouts decide star potential.
Precision BioSciences: High Upside, Zero Revenue—All Eyes on Clinical Proof
Precision BioSciences, Inc. keeps its Question Marks in early-stage, high-upside assets: PBGENE-DMD, PBGENE-HBV, and partnered ARCUS programs. None had 2025 product revenue, so value still depends on clinical proof, not cash flow. The upside is real, but so is failure risk.
| Asset | Status | Signal |
|---|---|---|
| PBGENE-DMD | Pre-commercial | 0 share |
| PBGENE-HBV | Early | 0 revenue |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.